

## Paul M. Tulkens

Professor Paul Tulkens is Emeritus Professor of Pharmacology, Drug Discovery and Development, and Rational Therapeutic Choices at the Faculties of Medicine and Pharmacy, *Université catholique de Louvain*, Belgium. He is also member of the Louvain Drug Research Institute of the same university. He was full Professor (until 2010) and the Founder and former Head (1993–2003) of the University's Unit of Cellular and Molecular Pharmacology, where he continues an active research programme. In 2001, he launched the Clinical Pharmacy Initiative in Belgium, and is currently a member of the Centre of Clinical Pharmacy at the *Université catholique de Louvain*. He also served (until 2010) as a Professor of Human Biochemistry and Biochemical Pathology at the Faculty of Medicine of the Université de Mons, Belgium.

Professor Tulkens' main research interests include: the discovery and development of new antibiotics; pharmacodynamics and pharmacokinetics of anti-infective drugs; pathophysiology of lysosomes; antibiotic toxicity (aminoglycosides, macrolides, oxazolidinones); chemotherapy of intracellular infection; and antibiotic efflux pumps and transporters. He is currently studying the intracellular activity of novel antibiotics, and participates European programmes aimed at developing the on-line monitoring of  $\beta$ -lactam antibiotics in severely ill patients and at assessing the potential of antibiotic combinations to increase efficacy while mitigating resistance.

He has published extensively on optimisation of drug usage and has contributed to public programmes for controlling the overuse of antibiotics in the community. He has authored about 300 original scientific papers and reviews, and several book chapters. He currently serves on the Editorial Board of *Antimicrobial Agents and Chemotherapy*, *Microbial Drug Resistance*, *Open Journal of Pharmacology*, *Infectious Diseases in Clinical Practice*, and *PeerJ*, and is Section Editor of the *International Journal of Antimicrobial Agents* and *Biomedical Research International*. He is also a reviewer for several journals. He is a representative of the International Society of Chemotherapy to the European Committee for Antibiotic Susceptibility Testing (EUCAST) and served on its Steering Committee from 2008 to 2010. He also acts as an evaluating expert to the Belgian Fund for Scientific Research, the US National Institutes of Health, and the European Medicines Agency.